

Curriculum Vitae for Henrik J. Ditzel

Name: Henrik J. Ditzel, MD, PhD, DMSc
Born: May 3, 1960 in Copenhagen, Denmark
Current positions: Professor, consultant, Head of Research Unit

Current business address: Department of Oncology, Odense University Hospital and Cancer and Inflammation Research, Department of Molecular Medicine, University of Southern Denmark.
J. B. Winsøvsvej 25, 3, 5000 Odense C
hditzel@health.sdu.dk , phone +45 60113781

Research Area

Molecular medicine, translation research, biomarkers, immunology and immunotherapy, disease mechanisms, preclinical evaluation, omics technologies, including genomic, transcriptomics, epigenomics, and proteomics), animal models, molecular and cellular cancer biology, functional studies, autoimmunity, infectious diseases.

Positions held:

1987-1988: Internship, Internal Medicine, Odense Hospital, Denmark
1988-1992: Research fellow at Dept. of Immunology, Odense University, Denmark
1992-1995: Sr. Research Associate, The Scripps Research Institute, La Jolla, CA,
1995-1997: Residency, Clinical Immunology, Tissue typing laboratory, Copenhagen University Hospital, Rigshospitalet, Denmark
1997-2001: Assistant Professor, The Scripps Research Institute, La Jolla, CA, USA
2001-2004: Associate Professor, The Scripps Research Institute, La Jolla, CA
2000-2004: Associate Director and Ass. Professor, UCSD Medical Center, San Diego
2003-present: Professor of Cancer Immunology and Biomedicine, SDU
2004-2008: Adjunct Associate Professor, UCSD Medical Center, San Diego
2004-present: Adjunct Professor, The Scripps Research Institute, La Jolla, CA
2004-2009: Center coordinator, Medical Biotechnology Center, SDU
2004-2006: Consultant, Dept. of Infectious Diseases, Odense University Hospital
2007-present: Consultant, Dept. of Oncology, Odense University Hospital
2010-present: Head of Research, Cancer and inflammation, SDU
2018-present: Professor in Precision Medicine
2018-present: Head of Research, Dept. of Oncology, Odense University Hospital

Academic Degrees

1987: M.D., Odense University, Denmark
1992: Ph.D. in Cancer Immunology, Odense University, Denmark
1996: Authorization for independent medical practice (B-authorization).
1999: Doctor of Medical Sciences, (dr.med., D.M.Sc), Odense University.
2001: Board Certification Diploma of American Board of Histocompatibility and Immunogenetics

Honors and Awards

Age and Edith Dyssegaards award, 1995
FIRST award, National Institute of Health NIH, USA 1998
IDEA II award, California Breast Cancer Program, USA, 1998
Elected member of American Society of Clinical Investigation, 2003
Danish Society for Cancer Research "Gårdejer Ingemann Petersen" honorary award, 2011
The Danish Research Result of Year 2014, Videnskab.dk
Order of the Dannebrog, (Knight of 1st Class) 2015

Assignments and Evaluations

Editorial board: Annexins

Ad Hoc. peer-reviewer for >25 different journals including Nature Immunology, Nature Biotech., Nature Genetics, J. Immunol., J. Mol. Biol., Mol. Cell. Proteomics and Cancer Res.

Member of the grant reviewing boards:

American Arthritis Foundation, Molecular Biology/Genetics Study Section: 2002-2005.
The Irish Science Foundation (SFI), Biomedical panel: 2008-2012.
The Danish Cancer Society Scientific committee: 2010-2015 (Chair 2013-2015)

DanishCancer Research Foundation 2010-2015 (Chair 2013-2015).

Evaluation of grants from:

The CancerInstitute, National Institute of Health, Bethesda, USA; National Institute ofAllergy and Infectious Diseases, NIH, Bethesda, USA; Cancer Research UK,London, UK; The Wellcome Trust, UK; John Simon Guggenheim Memorial Foundation,New York; Medical Research Committee, UK; The Arthritis Research Campaign,London, UK, The Swiss National Science Foundation, Switzerland, The AustrianScience Foundation, Austria, Agency for Science,Technology & Research (A*STAR), Singapore.

PhD evaluation committee member for >15 PhD students

Board Member

Chairman of The Scientific Board, Symphogen, Copenhagen (1999-2003)
NanoBic- a forum for nanobioscience research at SDU (2004-2008)
Graduate School of Immunology (2005-2011)
Graduate School of Oncology (Odense/Århus)(2011-present)
Danish Centre for Translational Breast Cancer Research (2007-)(Vice-Chair 2010-present)
Translational Research Centre-Towards individualized breast cancer treatment (2008-2012)
Grundforskningscenter of Excellence: Sino-Danish Breast Cancer Research Centre (2009-2015)
Lundbeck NanoCAN Research Center (2010-2015)
Graduate School of Oncology and Hematology (2011-present)
Danish Bioimaging Center (DamBic) (2009-present, Co-Director)
A Race against Breast Cancer (2010-present)
Danish Society for Molecular Medicine (2016-present)
Danish Comprehensive Cancer Center (2017-present)

Teaching

- * Developed and lectured at courses in immunology, cancer biology and diagnostics for medical students and master students at SDU.
- * Developed and lectured at post-graduate courses for physicians and PhD students.
- * Organized and chaired the PhD course Molecular Methods in Cancer Biology/Basic Cancer Biology at SDU, which has been running 2012, 2013, 2015

Research Group

Current research group consists of 21 members,including 5 post docs, 4 PhD students and 3 technicians.
Main supervisor for >15 phd students, who have obtained theirdegree. Supervised >20 master studentand pregraduate medical students in their 1 year thesis work.

Publications

155 scientific publications (149 in peer-reviewed scientific journals, 5 book chapters), including 22 as 1. author and 57 as senior author. Hirsch-index = 36 (Web of Science). Sum of times cited: 3500. Average citations per Item: 17.3. Most papers deals with cancer research and immunology. Journals include Nature Medicine, Nature Immunology, Nature Clin. Pract. Oncol., Nature Communications (2), PNAS (6), JAMA Oncol., J. Exp. Med. (2), JNCI, Blood, Cancer Res. (2), Clin. Cancer Res (2), J. Immunol (5), JBC (2), Mol. Cell. Proteomics (3).

Selected Publications

1. GohJY, M Feng, W Wang, G Oguz, SM Yatim, PL Lee, Y Bao, TH Lim, P Wang, WL Tam, ARKodahl, MB Lyng, S Sarma, SY Lin, A Lezhava, YS Yap, AS Lim, DSB Hoon, **HJ Ditzel**#, SC Lee#, EY Tan#, Q Yu#. Chromosome1q21.3 amplification is a trackable biomarker and actionable target for breastcancer recurrence. Nature Medicine, online25 September 2017 doi:10.1038/nm.4405 (IF 29.9). #corresponding authors
2. JacobsenK, J Bertran-Alamillo, MA Molina, CTeixidó, N Karachaliou, MH Pedersen, J Castellví, M Garzón, C Codony-Servat, JCodony-Servat, A Giménez-Capitán, A Drozdowskyj, S Viteri, MRLarsen, U Lassen, E Felip, TG Bivona#, **HJ Ditzel**#, R Rosell. Convergent Akt activationdrives acquired EGFR inhibitor resistance in lung cancer. NatureCommunications, 8:410, 2017 (IF 12.1). #corresponding authors
3. Alves C, D Elias, MB Lyng, M Bak, T Kirkegaard, AE Lykkesfeldt, **HJ Ditzel**. High CDK6 protects cells from fulvestrant-mediatedapoptosis and is a predictor of resistance to fulvestrant in estrogenreceptor-positive metastatic breast cancer. Clin Cancer Res, 22:5514-26 2016 (IF8.7).
4. Wee ZN, SM Yatim, VK Kohlabauer, M Feng, JY Goh, B Yi, P Leng Lee, SZhang, PP Wang, WL Tam, Y Cai, **HJ Ditzel** , DS Hoon, EY Tan, Q Yu.*IRAK1is a therapeutic target that drives breast cancer metastasis and resistance topaclitaxel*. Nature Communications, 6:8746, 2015. (IF 11.5)

5. **Ditzel HJ** and MB Lyng. *Advantages of multiple clinical tests for determining the optimum treatment strategy for ER-positive breast cancer.* Nature Clin. Pract. Oncol. 5:376-7, 2008. (IF14.1)

6. Schaller M, DR, Burton, **HJ Ditzel**. *Autoantibodies to GPI in rheumatoid arthritis: linkage between an animal model and human disease.* Nature Immunol., 2:746-753, 2001. (IF20.0)